|
Welcome
|
|
11 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| A Randomised Double-Blind, Double Dummy Trial to Compare the Efficacy and Safety of Arimidex with Tamoxifen as First line Therapy for Advanced Breast Cancer in Post-Menopausal Women |
| Source of record | UK Trials |
| ISRCTN | ISRCTN74551156 |
| Date ISRCTN assigned | 19/08/2002 |
| Local reference number(s) | ZEN1033IL/27 |
| Public title | A Randomised Double-Blind, Double Dummy Trial to Compare the Efficacy and Safety of Arimidex with Tamoxifen as First line Therapy for Advanced Breast Cancer in Post-Menopausal Women |
| Scientific title | |
| Acronym | Not Applicable |
| Disease/condition/study domain | Breast |
| Study hypothesis | Not provided at time of registration |
| Design/methodology | Randomised controlled trial |
| Research ethics review | Not provided at time of registration |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. Patients with locally advanced or metastatic breast cancer who are candidates to receive hormonal therapy as first line therapy for advanced disease (patients may have received adjuvant chemotherapy or hormonal therapy but patients who have received tamoxifen as adjuvant therapy must have an interval of at least 12 months since stopping tamoxifen and entry into this trial) 2. Post-menopausal defined as: a) Aged >50 years or who have not menstruated during the preceding 12 months or who have follicle-stimulating hormone (FSH) levels within the post-menopausal range b) Women aged <50 years who have FSH levels within the post-menopausal range 3. Hormone receptor (oestrogen receptor and or progesterone receptor) positive or unknown 4. Measurable or evaluable disease 5. No previous systemic therapy for advanced breast cancer 6. No drug-maintained menopausal status 7. No evidence of life threatening visceral disease 8. Life expectancy of >3 months 9. No treatment with a non-approved or experimental drug within the preceding 3 months before randomisation 10. No prior history of other malignancy other than breast cancer, except basal cell or squamous cell carcinoma of the skin or cancer of the cervix which has been satisfactorily controlled 11. No contraindications to protocol treatments |
| Participants - exclusion criteria | Not provided at time of registration |
| Patient information material | |
| Anticipated end date | 01/07/1998 |
| Status of trial | Completed |
| Target number of participants | Not provided at time of registration |
| Interventions | 1. Group A: Arimidex (anastrozole) 1 mg plus tamoxifen placebo daily 2. Group B: Tamoxifen 20 mg plus Arimidex placebo daily |
| Primary outcome measure(s) | Not provided at time of registration |
| Secondary outcome measure(s) | Not provided at time of registration |
| Sources of funding | AstraZeneca Pharmaceuticals |
| Sponsor name | AstraZeneca Clinical Research Group (UK) |
| Sponsor details | 10 Logie Mill Beaverbank Office Park Lovie Green Road Edinburgh United Kingdom EH7 4HG |
| Sponsor telephone | +44(0)1316523000 |
| Sponsor fax | +44(0)1315574858 |
| Sponsor email | sponsor@unknown.com |
| Sponsor website | http://www.astrazeneca.co.uk |
| Contact name | Dr - - |
| Contact details | UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA |
| Contact telephone | +44 (0) 20 7670 4723 |
| Contact fax | +44 (0) 20 7670 4818 |
| Contact email | register@ctu.mrc.ac.uk |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN74551156 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
|
|
| © 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | |
|
|
|
|